Olympus Corporation (OCPNF)
| Market Cap | 11.06B -16.8% |
| Revenue (ttm) | 6.30B +0.2% |
| Net Income | 541.04M +1.3% |
| EPS | 0.48 +4.6% |
| Shares Out | n/a |
| PE Ratio | 20.44 |
| Forward PE | n/a |
| Dividend | 0.19 (1.98%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 4,400 |
| Average Volume | 9,432 |
| Open | 9.49 |
| Previous Close | 9.50 |
| Day's Range | 9.49 - 9.49 |
| 52-Week Range | 8.00 - 14.00 |
| Beta | 0.19 |
| RSI | 42.06 |
| Earnings Date | May 12, 2026 |
About Olympus
Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platfo... [Read more]
Financial Performance
In fiscal year 2025, Olympus's revenue was 997.33 billion, an increase of 6.53% compared to the previous year's 936.21 billion. Earnings were 117.86 billion, a decrease of -51.41%.
Financial numbers in JPY Financial StatementsNews
Olympus Earnings Call Transcript: Q3 2026
Revenue guidance was revised down due to one-off ship holds and U.S. execution issues, but Q4 growth is expected. China is showing early signs of recovery, while FDA inspections and product holds continue to pose risks. Margin improvement targets remain unchanged.
Olympus Earnings Call Transcript: Q2 2026
Gradual revenue and margin growth are targeted, with a focus on innovation, restructuring, and disciplined capital allocation. New product launches and emerging market strategies underpin optimism, while restructuring and FDA remediation costs are being addressed.
Olympus Earnings Call Transcript: Q1 2026
Q1 FY2026 saw a 12% revenue decline and a 65% drop in adjusted operating profit, driven by tough comps, delayed purchases, and regulatory/tariff headwinds. Management expects recovery from Q2 with new product launches, cost control, and local production in China.
Olympus Earnings Call Transcript: Q4 2025
FY2025 saw record revenue and strong profit growth, led by North America, despite China headwinds and supply chain disruptions. FY2026 guidance anticipates steady growth, increased R&D investment, higher dividends, and a major share buyback, with U.S. tariff risks being closely monitored.
Olympus Earnings Call Transcript: Q3 2025
Revenue grew 9% year-on-year, led by strong North American and SEA performance, but China’s ongoing challenges prompted a downward revision in full-year guidance. Adjusted operating profit and margins improved, with management targeting a return to 20%+ margins in the medium term.
Olympus Earnings Call Transcript: Q2 2025
Record-high revenue and double-digit growth in core segments were achieved in fiscal 2023, with operating margin reaching 20%. Fiscal 2024 guidance projects continued growth, increased dividends, and major investments in quality and innovation, amid ongoing regulatory and market challenges.
Olympus shares drop over 5% after CEO resigns over drug allegation
Shares of Japanese camera giant Olympus Corp fell on Monday after the company announced the resignation of its chief executive officer over a drug allegation. In a notice, Olympus said that it receive...
Olympus CEO steps down amid illegal drug purchase allegations; endoscope manufacturer's shares drop 7%
Olympus Corp shares fell over 7% on Monday, marking the steepest intraday decline in nearly three months, following the announcement that CEO Stefan Kaufmann had resigned from all roles effective imme...
Olympus Earnings Call Transcript: Q1 2025
Q1 FY2025 saw 15% revenue growth and 21% higher operating profit, driven by strong North America performance and cost control. China remains a challenge, but guidance is unchanged, with robust U.S. growth and ongoing quality improvements supporting the outlook.
Olympus Earnings Call Transcript: Q4 2024
Olympus Earnings Call Transcript: Q3 2024
Olympus Corp. of the Americas to Host Panel Discussion on Lung Cancer Screening Guidelines and Eligibility
Lung Cancer Awareness Month panel will examine who is at risk for lung cancer and what they need to know about the screening process and treatment options CENTER VALLEY, Pa. , Nov. 9, 2023 /PRNewswire...
Olympus Earnings Call Transcript: Q2 2024
Olympus Issues Request to Discontinue Use of UHI-4 Insufflator Unit, Except in Cases Where No Alternative is Available
CENTER VALLEY, Pa. , Oct. 27, 2023 /PRNewswire/ -- Olympus Corporation has announced a field corrective action in the U.S. to address complaints of adverse events from over insufflation during use of ...
Healthcare creating more opportunities for tech investors, says Harris Financial's Jamie Cox
Jamie Cox, Harris Financial Group managing partner, joins 'The Exchange' to discuss investment opportunities in medical devices, the intersection of healthcare and technology, and top picks in the med...
Olympus Corp. of the Americas Named Founders Award Winner
Company recognized for administrative professionals' career advancement initiative, OA3 CENTER VALLEY, Pa. , July 6, 2023 /PRNewswire/ -- Olympus Corp. of the Americas (OCA) announced today that it re...
Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
CENTER VALLEY, Pa. , July 3, 2023 /PRNewswire/ -- Olympus Corporation has announced a voluntary field corrective action to address complaints of endobronchial combustion occurring when laser-compatibl...
Olympus Earnings Call Transcript: Q4 2023
Olympus Earnings Call Transcript: Q3 2023
Olympus Earnings Call Transcript: Q2 2023
Olympus nearing deal to sell microscope unit for over $2 billion - sources
Japan's Olympus Corp is close to selling its microscope unit to a private equity firm in a deal that could fetch more than 300 billion yen ($2.2 billion), three people with direct knowledge of the mat...